-
Octobre Rose - Une touche de rose pour mieux vivre avec la maladieDaiichi Sankyo2025-03-04 10:49:31Octobre Rose - Une touche de rose pour mieux vivre avec la maladie
-
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 TrialDaiichi Sankyo2024-04-29 13:30:49ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free
-
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer 03/04/2024Daiichi Sankyo2024-03-25 13:50:43Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small
-
Cancer du sein et de l’estomac - Accord conclu sur le prix d’Enhertu (trastuzumab déruxtécan) avec le CEPS pour deux de ses indicationsDaiichi Sankyo2024-03-01 16:58:18Cancer du sein et de l’estomac - Accord conclu sur le prix d’Enhertu (trastuzumab déruxtécan) avec le CEPS
-
Enhertu continues to demonstrate clinically meaningful tumour response in patients with HER2-mutant metastatic non-small cell lung cancerDaiichi Sankyo2023-12-15 15:08:43Enhertu continues to demonstrate clinically meaningful tumour response in patients with HER2-mutant metastatic
-
Daiichi Sankyo Showcases Progress in Developing New Standards of Care for Patients with Industry-Leading DXd ADC Portfolio Across Multiple Cancers at ESMODaiichi Sankyo2023-12-15 15:09:59Daiichi Sankyo Showcases Progress in Developing New Standards of Care for Patients with Industry-Leading DXd
-
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer 10/23/2023Daiichi Sankyo2023-12-15 15:54:54ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced
-
VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML 11/11/2023Daiichi Sankyo2023-12-13 16:38:05VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed
-
Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial 10/23/2023Daiichi Sankyo2023-12-15 15:12:22Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously
-
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial 10/23/2023Daiichi Sankyo2023-12-15 15:13:17Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with
FR/DSC/01/24/0002
